WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Belgium launches probe into suspected Russian interference in upcoming EU electionsHow the OJ Simpson saga became a unique American momentJudge orders exThree killed in Ethiopia shootout as regional rebellions spill into the capitalSudan's war began a year ago. Children are among its most fragile survivorsThree killed in Ethiopia shootout as regional rebellions spill into the capitalAbu Ghraib survivors bring their torture claims to a US courtAbu Ghraib survivors bring their torture claims to a US courtRussian authorities announced mass evacuation for floodMali's junta bans the media from reporting on political activities in a deepening crackdown
3.2478s , 6499.0546875 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Grasp news portal